121 related articles for article (PubMed ID: 12479850)
21. Phase I study of continuous infusion 6-thioguanine in patients with acute leukemia.
Powell BL; Lyerly ES; Motsinger CP; Cruz JM; Chorley HM; Hurd DD; Cooper MR
Leukemia; 1995 May; 9(5):770-3. PubMed ID: 7769838
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
Amadori S; Picardi A; Fazi P; Testi AM; Petti MC; Montefusco E; Mandelli F
Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
[TBL] [Abstract][Full Text] [Related]
23. Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?
Malek SN; Gore SD
Leuk Res; 2003 Jan; 27(1):1-3. PubMed ID: 12479845
[No Abstract] [Full Text] [Related]
24. Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Seiter K; Feldman EJ; Sreekantaiah C; Pozzuoli M; Weisberger J; Liu D; Papageorgio C; Weiss M; Kancherla R; Ahmed T
Leukemia; 2001 Jun; 15(6):963-70. PubMed ID: 11417484
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.
Levitt NC; Propper DJ; Madhusudan S; Braybrooke JP; Echeta C; Te Poele R; Davies SL; Flanagan E; Hickson ID; Joel S; Ganesan TS
Br J Cancer; 2005 Jul; 93(1):60-9. PubMed ID: 15956976
[TBL] [Abstract][Full Text] [Related]
26. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
[TBL] [Abstract][Full Text] [Related]
27. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Koller CA; Kantarjian HM; Feldman EJ; O'Brien S; Rios MB; Estey E; Keating M
Cancer; 1999 Dec; 86(11):2246-51. PubMed ID: 10590364
[TBL] [Abstract][Full Text] [Related]
28. Salvage therapy for relapsed or refractory childhood acute lymphocytic leukemia by alternative administration a lymphoid- and myeloid-directed chemotherapeutic regimen consisting of dual modulation of ara-C, hydroxyurea, and etoposide.
Higashigawa M; Hori H; Hirayama M; Kawasaki H; Ido M; Azuma E; Sakurai M
Leuk Res; 1997 Sep; 21(9):811-5. PubMed ID: 9393595
[TBL] [Abstract][Full Text] [Related]
29. Etoposide, 6-thioguanine and idarubicin, an oral combination regimen (ETI) for the induction treatment of acute leukemia.
Ruutu T; Elonen E
Hematol Oncol; 1991; 9(2):87-92. PubMed ID: 1869245
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
Kantarjian HM; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang LY; Rios MB; Keating MJ; Meyer M
Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
[TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
[TBL] [Abstract][Full Text] [Related]
32. Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates.
Perkins JB; Goldstein SC; Dawson JL; Kim J; Field TL; Partyka JS; Fields KK; Maddox BL; Simonelli CE; Neuger AM; Lush RM; Sullivan DM
Clin Cancer Res; 2011 Dec; 17(24):7743-53. PubMed ID: 22028494
[TBL] [Abstract][Full Text] [Related]
33. Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia.
Linkesch W; Thaler J; Gattringer C; Konwalinka G
Haematol Blood Transfus; 1990; 33():330-2. PubMed ID: 2323638
[No Abstract] [Full Text] [Related]
34. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
[TBL] [Abstract][Full Text] [Related]
35. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
Hijiya N; Gaynon P; Barry E; Silverman L; Thomson B; Chu R; Cooper T; Kadota R; Rytting M; Steinherz P; Shen V; Jeha S; Abichandani R; Carroll WL
Leukemia; 2009 Dec; 23(12):2259-64. PubMed ID: 19741725
[TBL] [Abstract][Full Text] [Related]
36. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group.
Saito T; Hatta Y; Hayakawa F; Takahashi T; Hagihara M; Iida H; Minauchi K; Yamazaki E; Sugiura I; Murayama T; Sakura T; Mori N; Imai K; Yahagi Y; Atsuta Y; Saito AM; Hirakawa A; Kiyoi H; Matsumura I; Miyazaki Y;
Int J Hematol; 2021 Mar; 113(3):395-403. PubMed ID: 33230647
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase.
Wilhelm M; O'Brien S; Rios MB; Estey E; Keating MJ; Plunkett W; Sorenson M; Kantarjian HM
Leuk Lymphoma; 1999 Aug; 34(5-6):511-8. PubMed ID: 10492074
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
39. Ph-positive acute lymphoblastic leukemia after long-term remission of Ph-positive acute myeloid leukemia.
Nishida H; Yoshimizu N; Ueno H; Fujita A; Kato T; Park JW; Yano T; Tobinai K; Ikeda Y
Leuk Res; 2007 Mar; 31(3):417-8. PubMed ID: 16730062
[No Abstract] [Full Text] [Related]
40. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.
Marsh JH; Kreis W; Barile B; Akerman S; Schulman P; Allen SL; DeMarco LC; Schuster MW; Budman DR
Cancer Chemother Pharmacol; 1993; 31(6):481-4. PubMed ID: 8453688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
